NovoCure Has Medicare Billing Privileges Reinstated by CMS

NovoCure ( (NVCR) ) just unveiled an announcement.

On February 2, 2026, Novocure Inc. disclosed that the Centers for Medicare & Medicaid Services had revoked its Medicare billing privileges retroactive to December 17, 2025, due to an administrative issue in its triannual re-validation rather than a substantive compliance failure. On February 24, 2026, CMS rescinded the revocation and reinstated Novocure’s billing privileges retroactively, and the company, which continued serving existing and new patients during the ineligible period, expects no ultimate impact on its ability to recognize revenue from those services.

The brief interruption in billing status highlights operational reliance on accurate administrative processes in U.S. government reimbursement systems but appears unlikely to affect Novocure’s financial reporting for the affected period. Stakeholders may view the quick reversal and retroactive reinstatement as limiting potential disruption to cash flows and signaling that the issue was procedural rather than a reflection of underlying regulatory risk.

The most recent analyst rating on (NVCR) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on NovoCure stock, see the NVCR Stock Forecast page.

Spark’s Take on NVCR Stock

According to Spark, TipRanks’ AI Analyst, NVCR is a Neutral.

NovoCure’s overall stock score is primarily impacted by its financial challenges, including negative profitability and high leverage. While there are positive developments, such as international expansion and regulatory approvals, these are offset by operational inefficiencies and valuation concerns. The technical indicators suggest a lack of strong momentum, further contributing to the moderate score.

To see Spark’s full report on NVCR stock, click here.

More about NovoCure

Novocure is a medical technology company focused on developing and commercializing cancer therapies, including products delivered through its U.S. subsidiary, Novocure Inc. The company operates within the healthcare sector and relies significantly on reimbursement from government payers such as Medicare for its patient services.

Average Trading Volume: 1,846,555

Technical Sentiment Signal: Sell

Current Market Cap: $1.28B

For a thorough assessment of NVCR stock, go to TipRanks’ Stock Analysis page.